2025
Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms
Su D, Brown L, Bansal V, Bakkila B, Concors S, Turaga K, Gunderson C, Bergsland E, Strosberg J, Halfdanarson T, Metz D, Kunstman J, Kunz P, Gangi A, Group P. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer 2025, 131: e35871. PMID: 40558053, DOI: 10.1002/cncr.35871.Peer-Reviewed Original ResearchConceptsManagement of neuroendocrine neoplasmsPeritoneal metastasisNeuroendocrine neoplasmsConsensus guidelinesManagement of peritoneal metastasesClinical management of patientsManagement of PMManagement of patientsComplex clinical challengeLevel of evidenceCytoreductive surgerySurgical resectionSystemic therapyClinical managementClinical challengeLow incidenceModified Delphi techniquePathway blockDisease gradeGrade 1Therapy conceptsHeterogeneous phenotypesFunctional syndromesMultidisciplinary approachMetastasisConsensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms
Su D, Brown L, Bansal V, Bakkila B, Concors S, Turaga K, Gunderson C, Bergsland E, Strosberg J, Halfdanarson T, Metz D, Kunstman J, Kunz P, Gangi A. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms. Annals Of Surgical Oncology 2025, 1-18. PMID: 40560496, DOI: 10.1245/s10434-025-17360-3.Peer-Reviewed Original ResearchPeritoneal metastasisCytoreductive surgeryConsensus guidelinesManagement of peritoneal metastasesClinical management of patientsManagement of PMManagement of patientsLevel of evidenceBackgroundNeuroendocrine neoplasmsSurgical resectionSystemic therapyNeuroendocrine neoplasmsClinical managementModified Delphi techniqueLow incidencePathway blockDisease gradeGrade 1Therapy conceptsHeterogeneous phenotypesFunctional syndromesMultidisciplinary approachRound IMetastasisNeoplasmsManagement of Patients with Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline
Howington J, Souter L, Arenberg D, Blasberg J, Detterbeck F, Farjah F, Lanuti M, Leighl N, Videtic G, Murthy S. Management of Patients with Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline. CHEST Journal 2025 PMID: 40562304, DOI: 10.1016/j.chest.2025.06.023.Peer-Reviewed Original ResearchStage I NSCLCNon-small cell lung cancerStereotactic body radiotherapyEpidermal growth factor receptorCell lung cancerOverall survivalLung cancerGrading of RecommendationsII NSCLCSurgical resectionEarly-stage non-small cell lung cancerLow operative risk patientsStage I lung cancerUsefulness of adjuvant chemotherapyPrimary treatment of patientsStage ITherapy improves overall survivalResected stage IBStage II NSCLCImproved overall survivalMutant lung cancerOperative risk patientsHilar lymph node samplingMinimally invasive approachTreatment of patientsIntrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel
Gujarathi R, Peshin S, Zhang X, Bachini M, Meeks M, Shroff R, Pillai A. Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel. Hepatology Communications 2025, 9: e0743. PMID: 40489757, PMCID: PMC12150937, DOI: 10.1097/hc9.0000000000000743.Peer-Reviewed Original ResearchConceptsBiliary tract cancerManagement of intrahepatic cholangiocarcinomaCirculating tumor DNAIntrahepatic cholangiocarcinomaMolecular testingUnresectable diseaseClinical managementAdvanced biliary tract cancerMolecular profiling of individual tumorsDrug target alterationInsufficient tissue samplesCurative treatment optionCurative intent treatmentPrimary liver malignancyMultidisciplinary team-based approachTissue samplesTissue-based analysisAvailability of tissue samplesLocoregional therapyNegative marginsSurgical resectionTumor DNAAdequate tissueBiliary malignancyClinical presentationInternational multicenter study of stereotactic radiosurgery for bladder cancer brain metastases
Perron R, Iorio-Morin C, Chytka T, Simonova G, Chiang V, Singh C, Niranjan A, Wei Z, Lunsford L, Peker S, Samanci Y, Peterson J, Ross R, Rusthoven C, Lee C, Yang H, Yener U, Sheehan J, Kondziolka D, Mathieu D. International multicenter study of stereotactic radiosurgery for bladder cancer brain metastases. Journal Of Neuro-Oncology 2025, 174: 235-241. PMID: 40249513, DOI: 10.1007/s11060-025-05039-4.Peer-Reviewed Original ResearchConceptsCancer brain metastasesInternational Radiosurgery Research FoundationStereotactic radiosurgeryBrain metastasesBrain metastases treated with stereotactic radiosurgeryFollow-upStudy of stereotactic radiosurgeryTime of stereotactic radiosurgeryEvaluate stereotactic radiosurgeryFractionated stereotactic radiosurgeryMedian marginal doseNon-urothelial histologyBrain metastasis diagnosisAdverse radiation effectsImaging follow-upInternational multicenter studyMarginal doseResults103 patientsMedian KPSTumor controlSystemic metastasesLeptomeningeal disseminationMedian survivalSurgical resectionCorticosteroid intakeSpontaneous esophageal rupture resulting in formation of multiple pulmonary artery pseudoaneurysms: A case report
Becker L, Cornman-Homonoff J. Spontaneous esophageal rupture resulting in formation of multiple pulmonary artery pseudoaneurysms: A case report. Radiology Case Reports 2025, 20: 3352-3355. PMID: 40297258, PMCID: PMC12035716, DOI: 10.1016/j.radcr.2025.03.083.Peer-Reviewed Original ResearchPulmonary artery pseudoaneurysmSpontaneous esophageal ruptureEsophageal ruptureArtery pseudoaneurysmDegree of clinical suspicionLife-threatening conditionSurgical resectionClinical suspicionEndovascular embolizationNecrotizing pneumoniaCase reportInterventional radiologyPrompt interventionPseudoaneurysmPatientsRupturePatient careResectionEmbolizationSurgeryPneumoniaSuspicionPapDiagnosisRadiologyNeoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial
Bilen M, Vo B, Liu Y, Greenwald R, Davarpanah A, McGuire D, Shiradkar R, Li L, Midya A, Nazha B, Brown J, Williams S, Session W, Russler G, Caulfield S, Joshi S, Narayan V, Filson C, Ogan K, Kucuk O, Carthon B, Del Balzo L, Cohen A, Boyanton A, Prokhnevska N, Cardenas M, Sobierajska E, Jansen C, Patil D, Nicaise E, Osunkoya A, Kissick H, Master V. Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. Nature Cancer 2025, 6: 432-444. PMID: 40016487, DOI: 10.1038/s43018-025-00922-5.Peer-Reviewed Original ResearchConceptsNonmetastatic clear cell renal cell carcinomaRenal cell carcinomaClear cell renal cell carcinomaCell renal cell carcinomaCD8+ T cellsT cellsCell carcinomaAdverse eventsStem-like CD8+ T cellsMetastatic renal cell carcinomaPalmar-plantar erythrodysesthesia syndromeSingle-arm clinical trialOral multikinase inhibitorDisease-free survivalPhase 2 trialSecondary end pointsCabozantinib treatmentNeoadjuvant settingStable diseaseBiopsy-provenPartial responseSurgical resectionOverall survivalMultikinase inhibitorMyeloid populationsLocal definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.
Dizman N, Doshi S, Knezevic A, Feinaj A, Sayegh N, Hobeika C, Alaghehbandan R, Rives H, Zengin Z, Braun D, Zibelman M, McGregor B, Hammers H, Ged Y, Ornstein M, Msaouel P, Hahn A, Voss M. Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study. Journal Of Clinical Oncology 2025, 43: 503-503. DOI: 10.1200/jco.2025.43.5_suppl.503.Peer-Reviewed Original ResearchLocal definitive therapySarcomatoid dedifferentiationMetachronous metastasesSystemic treatmentST cohortDuration of disease controlChromophobe renal cell carcinomaTreatment characteristics of patientsMetastatic disease diagnosisSingle-organ metastasisTreatment-free intervalTreatment-free survivalKaplan-Meier methodRenal cell carcinomaFisher's exact testCharacteristics of patientsMulti-institutional studyWilcoxon rank sum testRank sum testMetastatic sitesSurgical resectionDefinitive therapyRare subtypeMedian intervalCell carcinomaUtility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer.
Linhares S, Srikumar T, Shin C, Mathur M, Mongiu A, Leeds I, Pantel H, Cecchini M. Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer. Journal Of Clinical Oncology 2025, 43: 45-45. DOI: 10.1200/jco.2025.43.4_suppl.45.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNeoadjuvant immune checkpoint inhibitorsPathological stageDMMR tumorsPMMR tumorsColon cancerSurgical resectionT stageRadiographic stagePathologic complete response rateUtilization of computed tomographyClinically staged patientsNode negative tumorsRate of understagingComplete response rateLocally advanced diseaseNode-positive diseaseClinical tumor stageNode-positive tumorsUpfront surgical resectionCorrelated to pathological stagingPrimary tumor growthLocalized colon cancerLow relapse rateEarly stage tumorsSpike Ripples: Hidden Clues to the Mystery of the Epileptogenic Zone
Quraishi I. Spike Ripples: Hidden Clues to the Mystery of the Epileptogenic Zone. Epilepsy Currents 2025, 25: 101-103. PMID: 39780979, PMCID: PMC11705290, DOI: 10.1177/15357597241306610.Peer-Reviewed Original ResearchSpike ripplesFast ripplesInterictal biomarkerSurgical resectionEpileptogenic zoneMulticentre cohortResection volumePersistent seizuresEpileptogenic tissueILA-1Ripple rateImproved biomarkersSubjective outcomesEpileptiform spikesProportion of spikesResectionSubdural electrodesBiomarkersEpileptogenicityHigh-frequency oscillationsOutcomesILASubjectsIntracranial electroencephalogramTissuePheochromocytoma and MEN Syndromes
Carr Z, Farela A, Oprea A. Pheochromocytoma and MEN Syndromes. 2025, 333-342. DOI: 10.1093/med/9780190902001.003.0030.Peer-Reviewed Original ResearchMultiple endocrine neoplasiaInadequate surgical resectionManagement of PPGLsRare neuroendocrine tumorsDefinitive surgical managementResection of pheochromocytomaPreoperative medical managementDiligent postoperative careHigh-risk procedurePersistent vasoplegiaResected patientsSurgical resectionNeuroendocrine tumorsPostoperative bleedingRefractory hypertensionVasopressor supportHypertensive crisisPreoperative optimizationEndocrine neoplasiaABSTRACT PheochromocytomaPostoperative periodPerioperative considerationsVentricular dysrhythmiasAnesthesia techniquesPotential complications
2024
Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms
Uhlig J, Nie J, Gibson J, Cecchini M, Stein S, Lacy J, Kunz P, Kim H. Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports 2024, 14: 30536. PMID: 39690170, PMCID: PMC11652651, DOI: 10.1038/s41598-024-81518-4.Peer-Reviewed Original ResearchConceptsGEP-NEN patientsGastroenteropancreatic neuroendocrine neoplasmsOverall survivalGEP-NENsTreatment patternsSystemic therapyNeuroendocrine neoplasmsAssociated with improved survivalLow-grade diseaseNational Cancer DatabaseLonger overall survivalSite-specific incidenceDisease specific factorsG3 NENSurgical resectionCancer DatabaseImproved survivalLow-stageCox regressionImprove outcomesPatientsIncidence increasesInternational guidelinesInvestigate incidenceSurvivalThe evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review
Zolfaghari E, Dhanasopon A, Woodard G. The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review. Journal Of Thoracic Disease 2024, 0: 0-0. PMID: 39831209, PMCID: PMC11740046, DOI: 10.21037/jtd-24-245.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorEarly-stage non-small cell lung cancerAnaplastic lymphoma kinaseAdjuvant therapyCell lung cancerEarly-stage patientsSurgical resectionOverall survivalAdjuvant chemotherapyLung cancerSurvival benefit of adjuvant therapyAdjuvant platinum-based chemotherapyBenefit of adjuvant therapyHigh-risk pathologic featuresStage IB tumorsNational Clinical Trials RegistryPlatinum-based chemotherapyHigh-risk featuresCirculating tumor DNALandscape of adjuvant therapyLung cancer recurrenceGrowth factor receptorClinical Trials RegistryAdjuvant osimertinibUterine teratoma and the role of short-tandem repeat genotyping in understanding origins
AlAshqar A, Maruthi V, Abi-Raad R, Greenman M, Hui P, Ratner E, Altwerger G, Santin A, Andikyan V. Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins. Gynecologic Oncology Reports 2024, 56: 101652. PMID: 39698441, PMCID: PMC11652878, DOI: 10.1016/j.gore.2024.101652.Peer-Reviewed Case Reports and Technical NotesUterine teratomaPluripotent stem cellsMolecular testingRare tumorLimitations of diagnostic imagingHistory of vaginal bleedingShort tandem repeat genotypingStem cellsAdvanced molecular testingRepeat genotypingFallopian tube tissueGerm cell layersLoss of heterozygosityFour-week historyVaginal bleedingSurgical resectionOvarian counterpartRare entityUterine massPrimiparous womenEndometrial samplesFetal tissuesTeratomaPresence of tissueDiploid karyotypeElectrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review
Barbieri P, Posa A, Lancellotta V, Madoff D, Maresca A, Cornacchione P, Tagliaferri L, Iezzi R. Electrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review. Current Oncology 2024, 31: 7403-7413. PMID: 39590176, PMCID: PMC11592455, DOI: 10.3390/curroncol31110546.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesColorectal cancerComplete responseOverall survivalProgressive diseaseInclusion criteriaResection of CRC liver metastasesTreatment of CRC liver metastasisColorectal cancer liver metastasesSystematic searches of PubMedFrequent liver metastasesMedian overall survivalSecondary liver cancerFollow-up durationColorectal Liver MetastasesMultiple risk factorsCancer-related mortalitySearch of PubMedECT-related complicationsEvidence qualityLocoregional treatmentSurgical resectionIdentified articlesGRADE approachEmergent responsive neurostimulation in pediatric super‐refractory epilepsia partialis continua
Hadar P, Nanda P, Walsh K, McLaren J, Geffrey A, Simon M, Kahle K, Richardson R, Chu C. Emergent responsive neurostimulation in pediatric super‐refractory epilepsia partialis continua. Annals Of Clinical And Translational Neurology 2024, 11: 3320-3327. PMID: 39540465, PMCID: PMC11651186, DOI: 10.1002/acn3.52199.Peer-Reviewed Original ResearchMassive thymic hyperplasia in a toddler masquerading as a loculated pleural effusion: A case report
Zolfaghari E, Shaughnessy M, Wu H, Caty M, Christison-Lagay E, Hornick M. Massive thymic hyperplasia in a toddler masquerading as a loculated pleural effusion: A case report. Journal Of Pediatric Surgery Case Reports 2024, 110: 102885. DOI: 10.1016/j.epsc.2024.102885.Peer-Reviewed Original ResearchMassive thymic hyperplasiaChest X-rayThymic hyperplasiaCase reportComputed tomographyDifferential diagnosis of pediatric patientsSurveillance chest x-raysDiagnosis of pediatric patientsTrue thymic hyperplasiaRecurrent respiratory distressPost-operative coursePercutaneous core biopsyLoculated pleural effusionHistory of multiple admissionsPersistent respiratory symptomsSurgical resectionCore biopsyParapneumonic effusionPediatric patientsAbnormal findingsPleural effusionRight thoracotomyRare conditionRight hemithoraxSuspected pneumoniaEvaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma
Husain Z, Rybkin A, Lee V, Young M, Eskander A, Burtness B, Park H. Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e759-e760. DOI: 10.1016/j.ijrobp.2024.07.1668.Peer-Reviewed Original ResearchLymphovascular space invasionOral cavity carcinomaOverall survivalIntermediate-riskHigh riskT3/4 diseaseDistant metastasisN stageStandard riskPrediction of distant metastasisGrade 3 tumorsMedian follow-upNational Cancer DatabasePathological risk factorsOral cavity cancerKaplan-Meier methodLog-rank testSubsets of patientsHospital-based cohortClinical trial stratificationHigh-volume hospitalsT3/4 tumorsMedian followSurgical resectionIndividualized treatment selectionDatopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M, Tsiatis B, Chien A, Wallace A, Arora M, Rozenblit M, Hershman D, Zimmer A, Clark A, Beckwith H, Elias A, Stringer-Reasor E, Boughey J, Nangia C, Vaklavas C, Omene C, Albain K, Kalinsky K, Isaacs C, Tseng J, Roussos Torres E, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi M, Outhaythip A, Li W, Onishi N, Asare A, Beineke P, Norwood P, Brown-Swigart L, Hirst G, Matthews J, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky R, DeMichele A, Yee D, van ‘t Veer L, Hylton N, Esserman L. Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature Medicine 2024, 30: 3728-3736. PMID: 39277671, PMCID: PMC12044543, DOI: 10.1038/s41591-024-03266-2.Peer-Reviewed Original ResearchBreast cancerLikelihood of pathologic complete responseTreatment strategiesPathologic complete response rateEarly-stage breast cancerEarly surgical resectionTaxane-based regimenComplete response ratePathological complete responsePhase 2 trialBreast cancer subtypesEffective personalized treatmentHigh-risk stageMagnetic resonance imagingComplete responseDoxorubicin-cyclophosphamideNeoadjuvant treatmentSurgical resectionOcular eventsEfficacy analysisPrimary endpointTumor subtypesNew agentsCancer subtypesPatientsModern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-escalation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply